secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2023-05-31T23:59:59+00:00
Accession:  0001193125-23-157286
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Therapeutics appoints Gavin MacBeath as permanent CEO with increased compensation
--------------------------------------------------------------------------------

- Gavin MacBeath, Ph.D., appointed CEO and Class I Director effective May 24, 2023; previously acting CEO since March 2023.
- Base salary increased to $565,000 (from $470,000); target bonus raised to 50% of base (from 40%).
- Received stock option award for 1,121,300 shares at $2.49 per share; contingent on stockholder approval of equity plan amendment.
- Board also granted options for 7,403,100 shares aggregate to other recipients, subject to same amendment.
- Company highlights progress in hematologic and solid tumor programs, and collaboration with Amgen for Crohn's disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312523157286/0001193125-23-157286-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312523157286/d515205d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-157286

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer